|Systematic (IUPAC) name|
|Licence data||EMA: , US FDA:|
|Metabolism||By adenosine deaminase, to 9-β-D-arabinofuranosylguanine|
|Half-life||30 minutes (nelarabine)
3 hours (ara-G)
|Mol. mass||297.268 g/mol|
|(what is this?)|
Nelarabine is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and cytotoxicity. Pre-clinical studies suggest that T-cells are particularly sensitive to nelarabine. In October 2005, it was approved by the FDA for T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma that has not responded to or has relapsed following treatment with at least two chemotherapy regimens. It was later approved in the European Union in the October of 2005. Complete responses have been achieved with this medication.
It is marketed in the US as Arranon and as Atriance in the EU by GlaxoSmithKline.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|